- All Free Papers and Essays for All Students

Pharmaceutical Industry Financial Analysis 2011 - Pfizer, Gsk, Takeda, Astrazeneca

Autor:   •  January 11, 2012  •  Case Study  •  1,205 Words (5 Pages)  •  1,913 Views

Page 1 of 5

Our team has conducted financial analysis on 4 global pharmaceutical companies: Pfizer from U.S.,

GlaxoSmithKline („GSK‟) from UK, Takeda Pharmaceutical from Japan („Takeda‟) and AstraZeneca Plc also

from U.S. Together these 4 pharmaceutical products and services providers had sales of over $160 Billion in

2010. These established and mature markets of U.S., UK and Japan combined represent approximately 30% of

the global demand for pharmaceuticals. According to a latest research by RNCOS Industry Research Solutions

called “Global Pharmaceutical Market Forecast to 2012”, the industry is estimated to grow at 6.5% between

2011 through 2013. This is coming after a 2 year industry wide slow growth period (2008 to 2009). It is also

important to note that we have considered and presented the combined financial data of these 4 pharmaceuticals

as “Industry” for the various analysis and arguments throughout this paper.

Some Quick Facts:

Global pharmaceutical players having worldwide consumer base.

Above 4 pharmaceuticals have approximately 20% of the global market share as per 2010 global market

size of around $800 Billion.

The 4 employ over 280,000 personnel worldwide.

FINANCIAL ANALYSIS (based on ANNUAL REPORTS of 2008 - 2010):-

The following are the 3 most important factors affecting the profitability of these firms

Firstly, we have analyzed each pharmaceutical‟s margin contribution: Cost of Goods Sold (COGS), Research &

Development (R&D), Supplies & Administration (SG&A) and Profit margin (see below graphs). We were able

to conclude both R&D and SG&A as significantly greater expenses even higher than that of COGS, which

normally constitutes a larger portion of total expense breakup in other industries.

From the below graphical layout, one can determine the individual firm R&D expense is between the range of

29% (for Pfizer) to upwards of 46% (for GSK). Though the firms‟ actual production cost is kept low but their

R&D portion is significantly higher.


Download as:   txt (7.4 Kb)   pdf (143.9 Kb)   docx (13.9 Kb)  
Continue for 4 more pages »